Long-Acting Diabetes Treatments Approved
Two new diabetes treatments got a green light from the FDA today.
Those treatments are Novo Nordisk’s Tresiba (insulin degludec injection) and Ryzodeg 70/30 (insulin degludec/insulin aspart injection). These drugs are long-acting insulins that are only injected once or twice a day.
“Long-acting insulins play an essential role in the treatment of patients with type-1 diabetes and in patients with type-2 diabetes with advanced disease,” said Jean-Marc Guettier, MD, director of the Division of Metabolism and Endocrinology Products in the FDA’s Center for Drug Evaluation and Research, in a press release. “The FDA remains committed to support the development of innovative therapies for the treatment of diabetes.”